Key Takeaways ADMA posted $114.8M in Q1 revenues, driven by record Asceniv sales. The new process ups IG output by 20$500M revenue target for 2025. Despite gains, ADMA trades at 7.68x sales and faces EPS estimate cuts amid stiff plasma therapy competition. ADMA Biologics (ADMA) markets plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases.ADMA’s lead product, Asceniv, is a plasma-derived Intravenous Immune Globulin that contain ...